Publications by authors named "Eli Roth"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

988,923

Total Likes

18,916

Extended Reach

989,172

Social Features

4
P
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
Eli M Roth, John J P Kastelein, Christopher P Cannon, Michel Farnier, James M McKenney

J Clin Lipidol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.
Jennifer G Robinson, Michel Farnier, John J P Kastelein, Eli M Roth, Marja-Riitta Taskinen

J Clin Lipidol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
Dirk Müller-Wieland, Daniel J Rader, Patrick M Moriarty, Jean Bergeron, Gisle Langslet, Eli M Roth

J Clin Endocrinol Metab· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
Eli M Roth, Michael H Davidson

Rev Cardiovasc Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab for low-density lipoprotein cholesterol lowering.
Eli M Roth

Future Cardiol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety evaluation of evolocumab.
Eli M Roth

Expert Opin Drug Saf· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidrug Antibodies in Patients Treated with Alirocumab.
Eli M Roth, Anne C Goldberg, Alberico L Catapano, Albert Torri, George D Yancopoulos

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
Dirk J Blom, Michael J Koren, Eli Roth, Maria Laura Monsalvo, C Stephen Djedjos

Diabetes Obes Metab· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
Eli M Roth, Patrick M Moriarty, Jean Bergeron, Gisle Langslet, Garen Manvelian

Atherosclerosis· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.
Eli M Roth

Future Cardiol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo.
Peter P Toth, Sara C Hamon, Steven R Jones, Seth S Martin, Parag H Joshi, Eli M Roth

Lipids Health Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
Patrick M Moriarty, Eli M Roth, Adam Karns, Ping Ye, Shui-Ping Zhao

J Clin Lipidol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
Eli M Roth, James M McKenney

Future Cardiol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Dirk J Blom, C Stephen Djedjos, Maria Laura Monsalvo, Ian Bridges, Scott M Wasserman, Eli Roth

Circ Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels.
Eli M Roth, Maja Bujas-Bobanovic, Michael J Louie, Bertrand Cariou

Clin Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Richard L Dunbar, Stephen J Nicholls, Kevin C Maki, Eli M Roth, David G Orloff

Lipids Health Dis· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Hamed Emami, Esad Vucic, Sharath Subramanian, Amr Abdelbaky, Zahi A Fayad, Eli Roth

Atherosclerosis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
Michael J Koren, Eli M Roth, James M McKenney, Daniel Gipe, Corinne Hanotin

Postgrad Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Ï
ω-3 carboxylic acids for hypertriglyceridemia.
Eli M Roth

Expert Opin Pharmacother· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
Evan A Stein, Robert P Giugliano, Michael J Koren, Frederick J Raal, Eli M Roth

Eur Heart J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
Eli M Roth, Marja-Riitta Taskinen, Henry N Ginsberg, John J P Kastelein, Helen M Colhoun

Int J Cardiol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Daniel Gaudet, Dean J Kereiakes, James M McKenney, Eli M Roth, Corinne Hanotin

Am J Cardiol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Dirk J Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Eli Roth

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.
Eli M Roth, Philip Diller

Future Cardiol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis